Pacira BioSciences (PCRX) announced that the Centers for Medicare and Medicaid Services (CMS) has proposed the Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule for 2025. In this rule, Pacira’s lead drug, Exparel (bupivacaine liposome injectable suspension), is among six non-opioid treatments, out of which two are specific to ophthalmology, eligible for separate Medicare reimbursement in both ambulatory surgical centers (ASC) and hospital outpatient (HOPD) set ...